Taiwan-Biotechnology firm expand investment THB2.5 billion in Thailand by announced the establishment of Aesthetic Alliance All Co Ltd (AAA), a joint venture with Thailand’s K.N.A. Interpharma Co Ltd and four prominent aesthetic clinic executives.
Dr. Aaron Shia-Hsien Hsia, Chairman of Diamond Biotechnology Co Ltd, a company specializing in research and development, manufacturing, and sales of medical equipment and skincare products, stated at a press conference today (July 15, 2025) that
Diamond Biotechnology will hold a 49% stake in AAA.
The joint venture will have a registered capital of THB500 million. The remaining 51% will be held by its five Thai partners.
The Thai partners include K.N.A. Interpharma Co Ltd, a pharmaceutical importer.
The individual partners are Dr. Rassapoom Sumaetheiwit M.D., a board-certified dermatologist and founder of Rassapoom Clinic,
who will also serve as an advisor in product development tailored to aesthetic medical needs.
Joining him are Dr. Piyawat Hirunnard M.D., executive and founder of Kay Hay Clinic Partner;
Dr. Nattaya Rakpuang M.D., gynecologist and founder of Dr. Aomthong Clinic; and
Dr. Kittitad Sinpipatporn M.D., executive and founder of La Ferly Clinic.
Dr. Hsia further detailed that the manufacturing plant, with an investment exceeding THB2 billion, is slated to begin construction on January 1, 2025.
Production is expected to commence in 2026, aiming to meet both Thai domestic demand and export needs.
An additional budget of over THB2 billion has been allocated for infrastructure, machinery, research and development (R&D), and four patented aesthetic medical instrument products.
The first two products to be manufactured are Miracal Thread Lifting and NeoFilera, which primarily utilizes poly-lactic acid.
The next two products are new and are scheduled for launch next year.
Taiwan-Biotechnology firm expand investment in Thailand
“We decided to expand our investment and build a new medical manufacturing plant in Thailand
because of the country’s potential to become a medical hub in Southeast Asia, particularly in aesthetic medicine,” Dr. Hsia explained.
“Thailand is recognized for its highly skilled medical professionals, the rapid growth of its aesthetic medicine sector,
favorable tax incentives, and supportive investment policies.”
He emphasized the crucial role of their existing partnership:
“Most importantly, our long-standing partnership with K.N.A. over the past three years has built strong mutual trust.
We’ve witnessed their expertise in management, marketing, and their expansive network of aesthetic medical professionals—all of which will be vital in expanding our presence in Thailand.”
Taiwan-Biotechnology firm expand investment
To Create job and knowledge transfer to Thai staff
Upon commencing operations, the manufacturing plant is expected to create 50 jobs for Thai citizens, with plans to employ over 200 Thai staff within the next two to three years.
The company also has a policy to share medical knowledge and provide R&D training for the Thai team.
This initiative aims to enhance Thai skills in medical research and development, ultimately helping Thailand evolve into a medical hub in ASEAN, capable of exporting, rather than solely importing, medical products, particularly in the field of beauty medicine.
Thailand is Medical hub in Asean
Dr. Hsia outlined the company’s business strategy, stating that approximately 70% of the manufacturing plant’s total production capacity in Thailand will be allocated for export, with the remaining 30% designated for the Thai market.
In its first year of operation, the plant is projected to produce around 200,000 Miracal Thread Lifting threads per month and 100,000 bottles of NeoFilera per year.
The company plans to increase production capacity in the subsequent years to meet growing market demand.
Thailand will serve as the export base for markets including Indonesia, Malaysia, Vietnam, and China in the first stage.
As the next stage will expand the market to Cambodia, Laos, Myanmar, the Philippines, Singapore, Timor-Leste, and Brunei, as well as providing a strategic entry point into the Middle East.
3-years generate income to cover investment value
“We forecast that the joint venture company, AAA, will generate a total revenue of THB500 million in its first year of operation,” Dr. Hsia stated.
“Over the next two years, we anticipate an annual growth rate of over 20% per year, and AAA is expected to generate enough income to cover its investment within three years of commencing operations.”
Diamond Biotechnology Co Ltd is a publicly listed company on the Taiwan Emerging Stock Market, currently operating three beauty pharmaceutical manufacturing plants in Taiwan.
The investment in Thailand marks the company’s first beauty pharmaceutical manufacturing plant outside of Taiwan.
Dr. Hsia also revealed plans for the company to invest in building another beauty pharmaceutical manufacturing plant in China within the next two to three years.
Diamond Biotechnology Co. Ltd. expects its total revenue to reach US$30 million this year, an increase from US$25 million at the end of 2024.
Currently, 90% of its total revenue comes from the Taiwan market, with the remaining 10% from export markets.
Thailand’s medical move from Import to Export
Nadrincha Pathan, President of K.N.A. Interpharma Co. Ltd., expressed his belief that this joint venture will transform Thailand’s role from an importer of medical products to an exporter, particularly in the realm of beauty medical products, serving both domestic and global demand.
The plant will apply to get tax incentive with Thailand’s Board of Investment after the established already complete.
“The global market size for beauty medicine products is worth over THB100 billion a year,” Nadrincha stated.
“When we kick off the medicine manufacturing plant in Thailand, we’ll gain a share in this global market.
This also presents an opportunity to share knowledge with Thai people for researching and developing beauty medicine products.”
Thailand’s Surgery and Aesthetic Market Value THB76.5 billion
Dr. Rassapoom Sumaetheiwit, M.D., a board-certified dermatologist, founder of Rassapoom Clinic, and a key partner in the joint venture,
added that Thailand’s aesthetic medicine and surgery market continues to grow and holds immense potential.
Statistics from the Department of Business Development, Ministry of Commerce, indicate that
Thailand’s aesthetic and beauty industry has enjoyed continuous growth over the past five years and boasts a strong national-level partnership.
According to forecasts by Kasikorn Research Center, the value of Thailand’s cosmetic surgery and aesthetic business is expected to reach THB76.5 billion in 2025, an increase of 2.8% from 2024.
“Although Thailand’s economy has seen slight growth this year, it hasn’t impacted the demand for aesthetic business,” he said.
“Our customers continue to visit our clinic and are willing to pay for their treatment.”
He further added that investing in beauty pharmaceutical manufacturing presents an opportunity to bring world-class technology and innovation into Thailand.
This will raise treatment standards in aesthetic clinics, boost consumer confidence,
and increase acceptance of domestically produced, globally standardized products.
Moreover, moving production to Thailand will reduce costs for consumers, eliminate dependency on imports, generate national income,
and create local job opportunities.
Relate News : https://bangkokx.me/taiwan-investment-15072025/
Source : https://www.diamond-biotechnology.com/en/about-us/
